Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. NTHI
NTHI logo

NTHI Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy NeOnc Technologies Holdings Inc (NTHI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
5.450
1 Day change
-16.02%
52 Week Range
12.990
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

NeOnc Technologies Holdings Inc (NTHI) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company shows weak financial performance, no significant trading trends, and lacks positive catalysts or strong technical signals to support a buy decision.

Technical Analysis

The stock's MACD is slightly positive but contracting, RSI is neutral, and moving averages are bearish. Key support levels are at 4.657 and resistance at 5.589. Overall, the technical indicators do not suggest a strong buy opportunity.

Positive Catalysts

  • NULL identified. There is no recent news or significant trading activity from insiders or hedge funds.

Neutral/Negative Catalysts

  • The company's financials show a complete revenue drop (-100% YoY), with a significant net income loss and negative EPS. No recent news or events to drive positive sentiment.

Financial Performance

In Q4 2025, the company's revenue dropped to 0 (-100% YoY), net income increased to -15,524,104 (up 589.05% YoY), and EPS improved to -0.73 (up 508.33% YoY). Despite slight improvements in net income and EPS, the financials remain weak overall.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available.

Wall Street analysts forecast NTHI stock price to rise
Analyst Rating
0
Wall Street analysts forecast NTHI stock price to rise
Buy
Hold
Sell
0
Current: 6.490
sliders
Low
0
Averages
0
High
0
0
Current: 6.490
sliders
Low
0
Averages
0
High
0
BTIG
Thomas Shrader
Buy
initiated
$15
AI Analysis
2026-04-24
Reason
BTIG
Thomas Shrader
Price Target
$15
AI Analysis
2026-04-24
initiated
Buy
Reason
BTIG analyst Thomas Shrader initiated coverage of NeOnc Technologies with a Buy rating and $15 price target. The company is taking a multi-pronged approach by improving central nervous system delivery of agents with established antitumor activity such as temozolomide and also by developing novel agents active against hard-to-treat CNS tumors, the analyst tells investors. The key catalysts for the stock are incremental data sets supporting activity of its two lead drugs in difficult-to-treat patients expected later in 2026 and 2027, the analyst added.

People Also Watch